Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -29.5 Million USD | 33.59% |
| 2021 | -44.43 Million USD | -98.35% |
| 2020 | -22.06 Million USD | 22.99% |
| 2019 | -28.74 Million USD | -12.96% |
| 2018 | -23.83 Million USD | -77.29% |
| 2017 | -19.67 Million USD | -88.89% |
| 2016 | -7.86 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -869 Thousand USD | -106.33% |
| 2023 Q2 | 13.73 Million USD | 322.34% |
| 2023 Q1 | -6.17 Million USD | 15.63% |
| 2022 Q1 | -7.29 Million USD | 26.84% |
| 2022 FY | - USD | 33.59% |
| 2022 Q3 | -7.28 Million USD | 4.19% |
| 2022 Q2 | -7.6 Million USD | -4.29% |
| 2022 Q4 | -7.32 Million USD | -0.45% |
| 2021 FY | - USD | -98.35% |
| 2021 Q2 | -6.86 Million USD | -0.81% |
| 2021 Q1 | -6.8 Million USD | -16.92% |
| 2021 Q4 | -9.96 Million USD | 52.37% |
| 2021 Q3 | -20.93 Million USD | -205.0% |
| 2020 Q1 | -6.47 Million USD | -13.76% |
| 2020 Q4 | -5.82 Million USD | -0.54% |
| 2020 Q3 | -5.79 Million USD | -39.67% |
| 2020 FY | - USD | 22.99% |
| 2020 Q2 | -4.14 Million USD | 35.92% |
| 2019 Q3 | -7.3 Million USD | 10.67% |
| 2019 Q1 | -7.65 Million USD | -37.28% |
| 2019 FY | - USD | -12.96% |
| 2019 Q4 | -5.68 Million USD | 22.15% |
| 2019 Q2 | -8.18 Million USD | -6.86% |
| 2018 Q2 | -7.53 Million USD | -3.49% |
| 2018 FY | - USD | -77.29% |
| 2018 Q4 | -5.57 Million USD | -8.17% |
| 2018 Q3 | -5.15 Million USD | 31.57% |
| 2018 Q1 | -7.28 Million USD | -89.02% |
| 2017 Q1 | -3.4 Million USD | 0.0% |
| 2017 Q2 | -1.79 Million USD | 47.3% |
| 2017 Q3 | -5.47 Million USD | -205.24% |
| 2017 Q4 | -3.85 Million USD | 29.66% |
| 2017 FY | - USD | -88.89% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -6496.586% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 74.13% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -87.209% |
| Better Therapeutics, Inc. | -38.26 Million USD | 22.884% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 22.89% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -64.962% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 12.531% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 11.587% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 72.254% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -3130.09% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 9.162% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 36.807% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -419.129% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -81.005% |
| Molecular Templates, Inc. | 1.43 Million USD | 2163.357% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -112.654% |
| NexImmune, Inc. | -28.16 Million USD | -4.752% |
| Orgenesis Inc. | -60.71 Million USD | 51.405% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 42.477% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -40090.149% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -82.753% |
| Scopus BioPharma Inc. | -11.71 Million USD | -151.905% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 94.535% |
| Statera Biopharma, Inc. | 38.93 Million USD | 175.783% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -328.617% |
| Trevena, Inc. | -35.28 Million USD | 16.385% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -52541.344% |
| Vaccinex, Inc. | -19.74 Million USD | -49.413% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -2718.206% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 37.036% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -306.25% |